RFL Rafael Holdings, Inc.
USReal EstateAs of 2026-07-09 16:00
Why RFL matters now
Rafael Holdings, Inc. (RFL) is a US stock in Real Estate. The latest InvestLog snapshot shows $2.27 with -7.35% on the session and $83.4M in market capitalization; recent performance reads 1-month +102.22% and YTD +131.36%.
The latest financial table shown here is Q3 2026, with revenue of $179.0K, net income of $-4.2M, and EPS of $-0.08. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -31.9%.
The latest indexable market news headline is "Sekur Private Data Appoints Special Operations Communications Chief Master Sergeant (Ret.) Rafael Beltran to Its OpsTech Special Advisory Board" from Accesswire.
Additional event context on this page matters because recent insider activity includes JONAS HOWARD S filing F-InKind. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
1.86
P/S
102.38
EV/EBITDA
-2.01
DCF Value
$1.00
FCF Yield
-31.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
74.4%
Operating Margin
-3717.2%
Net Margin
-3321.7%
ROE
-39.0%
ROA
-35.4%
ROIC
-44.5%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2026 | $179.0K | $-4.2M | $-0.08 |
| Q2 2026 | $211.0K | $-6.4M | $-0.13 |
| Q1 2026 | $240.0K | $-9.8M | $-0.19 |
| Q4 2025 | $350.0K | $-12.1M | $-0.28 |
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Real Estate
Industry
Real Estate - Services
Country
US
Exchange
—
Beta
0.54
Rafael Holdings, Inc. holds strategic investments in both early-stage and clinical pharmaceutical companies, alongside a portfolio of commercial real estate assets situated in the United States and Israel. The company's business activities are structured into two primary divisions: Pharmaceuticals and Real Estate. Its Real Estate segment manages and leases a commercial office complex, which features an integrated 800-space public parking facility. The Pharmaceutical division, conversely, focuses on developing and bringing to market therapies designed to capitalize on the metabolic distinctions between healthy cells and malignant ones. The firm's flagship drug candidate is CPI-613 (devimistat), currently undergoing evaluation in numerous clinical trials, including two pivotal Phase III registrational studies for the treatment of advanced pancreatic cancer and relapsed/refractory acute myeloid leukemia. Rafael Holdings, Inc. is headquartered in Newark, New Jersey.